Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD158k Is a Reliable Marker for Diagnosis of Sézary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells
Hélène Moins‐Teisserenc, Magali Daubord, Emmanuel Clave, et al.
Journal of Investigative Dermatology (2014) Vol. 135, Iss. 1, pp. 247-257
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Single-cell heterogeneity in Sézary syndrome
Terkild B. Buus, Andreas Willerslev-Olsen, Simon Fredholm, et al.
Blood Advances (2018) Vol. 2, Iss. 16, pp. 2115-2126
Open Access | Times Cited: 97
Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients
Stéphanie E. Boonk, Willem H. Zoutman, Anne Marie‐Cardine, et al.
Journal of Investigative Dermatology (2016) Vol. 136, Iss. 7, pp. 1364-1372
Open Access | Times Cited: 89
CCR4 as a Therapeutic Target for Cancer Immunotherapy
Osamu Yoshie
Cancers (2021) Vol. 13, Iss. 21, pp. 5542-5542
Open Access | Times Cited: 83
Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
Adèle de Masson, Delphine Darbord, Gábor Dobos, et al.
Blood (2021) Vol. 139, Iss. 12, pp. 1820-1832
Open Access | Times Cited: 50
CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driver
Jan P. Nicolay, Jana D. Albrecht, Silvia Alberti Violetti, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 7, pp. 1660-1671
Open Access | Times Cited: 42
Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity
Marie Roelens, Marc Delord, C. Ram‐Wolff, et al.
Blood (2017) Vol. 130, Iss. 12, pp. 1468-1471
Open Access | Times Cited: 51
Novel targeted therapies of T cell lymphomas
Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 48
Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics
Pedro Horna, Sa A. Wang, Kristy Wolniak, et al.
Cytometry Part B Clinical Cytometry (2020) Vol. 100, Iss. 2, pp. 142-155
Open Access | Times Cited: 44
Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways
Kalyani Patil, Shilpa Kuttikrishnan, Abdul Quaiyoom Khan, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 382-399
Open Access | Times Cited: 40
Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome
Safa Najidh, Cornelis P. Tensen, Alita J. van der Sluijs‐Gelling, et al.
Blood (2021) Vol. 138, Iss. 24, pp. 2539-2554
Open Access | Times Cited: 38
Flow cytometry for the assessment of blood tumour burden in cutaneous T‐cell lymphoma: towards a standardized approach
Maarten H. Vermeer, Hélène Moins‐Teisserenc, M. Bagot, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 1, pp. 21-28
Open Access | Times Cited: 23
Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome
Charlotte Hurabielle, Nicolas Thonnart, C. Ram‐Wolff, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 14, pp. 3619-3627
Open Access | Times Cited: 45
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Lisa Argnani, Alessandro Broccoli, Pier Luigi Zinzani
Cancer Treatment Reviews (2017) Vol. 61, pp. 61-69
Closed Access | Times Cited: 34
Brentuximab vedotin in T-cell lymphoma
Carrie Van Der Weyden, Michael Dickinson, James C. Whisstock, et al.
Expert Review of Hematology (2018) Vol. 12, Iss. 1, pp. 5-19
Closed Access | Times Cited: 34
Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome
Tomonori Oka, Tomomitsu Miyagaki
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 31
Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR 3 DL 2 marker
Marie Roelens, Adèle de Masson, C. Ram‐Wolff, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 6, pp. 1415-1422
Closed Access | Times Cited: 30
Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome*
Marie Roelens, Adèle de Masson, Anaïs Andrillon, et al.
British Journal of Dermatology (2022) Vol. 186, Iss. 6, pp. 1010-1025
Closed Access | Times Cited: 18
T cells in the skin: Lymphoma and inflammatory skin disease
Ben Roediger, Christoph Schlapbach
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 4, pp. 1172-1184
Open Access | Times Cited: 17
Naïve/memory T‐cell phenotypes in leukemic cutaneous T‐cell lymphoma: Putative cell of origin overlaps disease classification
Pedro Horna, Lynn C. Moscinski, Lubomir Sokol, et al.
Cytometry Part B Clinical Cytometry (2018) Vol. 96, Iss. 3, pp. 234-241
Open Access | Times Cited: 29
Sézary syndrome: old enigmas, new targets
Jan P. Nicolay, Moritz Felcht, Kai Schledzewski, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2016) Vol. 14, Iss. 3, pp. 256-264
Open Access | Times Cited: 28
Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma
Philipp Licht, Volker Mailänder
Cells (2022) Vol. 11, Iss. 3, pp. 328-328
Open Access | Times Cited: 14
Monoclonal Antibodies
Larisa J. Geskin
Dermatologic Clinics (2015) Vol. 33, Iss. 4, pp. 777-786
Open Access | Times Cited: 27
CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214
Bernice M. Benoit, Neha Jariwala, Geraldine M. O’Connor, et al.
Archives of Dermatological Research (2016) Vol. 309, Iss. 1, pp. 11-19
Open Access | Times Cited: 24
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells
F. Amatore, Nicolás Ortonne, Marc Lopez, et al.
Blood Advances (2020) Vol. 4, Iss. 20, pp. 5203-5214
Open Access | Times Cited: 21
Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
Ari Pelcovits, Thomas Ollila, Adam J. Olszewski
Cancer Management and Research (2023) Vol. Volume 15, pp. 989-998
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top